• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services


  • Print
  • Share
  • E-mail

Permax (pergolide mesylate) Feb 2003

Audience: Neurologists and other healthcare professionals

Lilly and FDA revised the WARNINGS section of the prescribing information to inform healthcare professionals of reports of cardiac valvulopathy involving one or more valves in patients receiving Permax therapy.

[February 2003 - Letter - Lilly]